Biotech Conagen Acquires Production Platform of Therapeutic Proteins

The technology should reduce costs to patients and accelerate drug development  

BEDFORD, Mass., Aug. 21, 2019 /PRNewswire/ -- Conagen, a vertically integrated synthetic biology company located in Boston's biotech corridor, announced today that it has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins.

At Conagen, we’re changing the way natural products are manufactured, with molecule-per-molecule precision and customization. Through synthetic biology, we uncover the metabolic pathways in nature, engineer unique microbes, and develop high-quality products through specialized fermentation. We serve the food and beverage, fragrance, nutrition, renewable materials, and pharma markets. (PRNewsfoto/Conagen)

The acquisition includes several patents covering the platform and all associated tangible assets, establishing Conagen as a leading developer of active pharmaceutical ingredients.

In addition to a suite of more than 10 already developed therapeutic glycoproteins, the host platform will be used by Conagen for development of both novel and generic drugs.

Industrial fermentation typically employs microbes which can be cultured rapidly at the largest scales without cell disruption or losses in productivity.  Characteristics of these therapeutics, which include desirable glycostructures and other post-translational modifications, have limited their commercial production to fragile mammalian cell systems at relatively small scales. 

"One of the most exciting features of this host organism is its ability to express glycoproteins harboring glycostructures which promote the desired immune cell functions.  This is a very unusual feature to find in a robustly fermentable microbe.  It is also advantaged by its ability to tolerate the engineering required to customize these glycostructures while preserving the microbe's robustness," said Vice President of Research and Development, Casey Lippmeier

The platform will reduce costs, and the savings can be passed down to patients. This is important to the pharmaceutical industry which is under increasing pressure to reduce time and capital in developing drugs," said Oliver Yu, Ph.D., co-founder, and CEO of Conagen.

The largest category of therapeutic glycoproteins is the blockbuster monoclonal antibodies upon which the entire $100 billion immunotherapy and antibody-drug conjugate market is based. 

More about Conagen: Making Impossible Possible®

Conagen is a leader in bioengineering. The company's scientists and engineers use the latest synthetic biology tools to design metabolic pathways, improve production organisms, and optimize production procedures. It focuses on bioproduction of high-value ingredients for food, nutrition, flavor and fragrance, pharmaceutical, and renewable materials industries. For more information, visit the official company website at www.conagen-inc.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biotech-conagen-acquires-production-platform-of-therapeutic-proteins-300905321.html

SOURCE Conagen

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.